PAREXEL International Corporation (PAREXEL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications, consulting, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries. It operates it three segment Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS) and Perceptive Informatics, Inc.
You might be interested in …
Canadian securities regulators seek comment on activist short selling
The Canadian Securities Administrators (CSA) published a consultation paper to facilitate discussion about activist short selling
BlackBerry Limited $BBRY
BlackBerry Announces Completion of Acquisition of Additional U.S. $250 Million Debentures by Fairfax More Developers Prefer Google’s Android to Apple’s iOS, Say Studies The company sells its BlackBerry wireless solutions through wireless communications carriers and […]
Morningstar: Why We’ve Downgraded ARK Innovation
ARK Innovation ETF (ARKK) shows few signs of improving its risk management or ability to successfully navigate the challenging territory it explores. Its Morningstar Analyst Rating drops to Negative from Neutral as its People and Parent ratings both drop to Below Average from Average.
Latest Posts
